Drug intelligence / Profile preview

qav680 + cetirizine placebo

Development stage: Discontinued
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

QAV680 (NVP-QAV680) is a potent and selective CRTH2 (chemoattractant receptor homologous expressed on Th2 cells) receptor antagonist developed by Novartis. It has low nanomolar functional potency for inhibiting CRTH2-driven human eosinophil and Th2 lymphocyte activation in vitro. The combination with cetirizine placebo likely represents a clinical trial design where QAV680 was tested against or alongside cetirizine placebo for allergic conditions.

Targets

PTGDR2 (Prostaglandin D2 receptor 2)

Beyond the preview

Go deeper on qav680 + cetirizine placebo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on qav680 + cetirizine placebo.

Explore the full profile